Evidence map›Paper›PMID 21930088›Full record

ReviewUrologic oncology

Magnetic resonance spectroscopy: a promising tool for the diagnostics of human prostate cancer?

Johannes Kurth, Elita Defeo, Leo L Cheng

Abstract readReview
In one paragraph

Review in Urologic oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Comparing signal-to-noise ratio for prostate imaging at 7T and 3T.Journal of magnetic resonance imaging : JMRI · 2019
    Article
  3. MRS Shimming: An Important Point Which Should not be Ignored.Journal of biomedical physics & engineering · 2018
    Article
  4. Magnetic resonance imaging for prostate cancer clinical application.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Johannes KurthCharite Universitatsmedizin, Berlin, Germany.
Elita Defeo
Leo L Cheng
Charité - Universitätsmedizin Berlin · DEHarvard University · USMassachusetts General Hospital · US

Funding

Characterizing Prostate Cancer By ex vivo MRS SignaturesR01CA115746 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHENG, LEO L · 2006 to 2017
$6.4M
Detection of Lung Cancer Risks for Serum MetabolomicsR21CA141139 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHENG, LEO L · 2010 to 2011
$432k
NCI NIH HHS CA115746NCI NIH HHS CA115746S2NCI NIH HHS CA141139NCI NIH HHS R01 CA115746NCI NIH HHS R21 CA141139
6 · The paper itself

Abstract

backgroundProstate cancer (CaP) is one of the topmost diagnosed malignant diseases worldwide. In developed countries, early cancer detection methods have led to an increase of incidence rates over the last decades; however, with great variance of the prognosis. There is no diagnostic tool for an exact prediction of tumor aggressiveness, thus there is a lack of adequate and optimal treatment planning.

methodsElectronic databases (Medline, PubMed) were scanned for scientific literature. Basic concepts of magnetic resonance spectroscopy (MRS), important results and its clinical applications were extracted and reviewed in this article.

conclusionsMRS provides crucial information about the metabolic status of human prostate samples while preserving the specimens for further investigations. Single metabolites and metabolomic profiles can be quantified to distinguish benign from malignant tissue and to predict aggressiveness, such as the recurrence rates of CaP. Studies are also anticipating that MRS might be beneficially applicable for in vivo investigations in the future.

Indexed as

Magnetic Resonance SpectroscopyHumansMalePrognosisProstatic Neoplasms

Identifiers

PMID21930088
PMCPMC4339019
OpenAlexW2080891701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.